In obesity, oxygen supply cannot meet the demand of expanding adipose, resulting in relative hypoxia within adipose tissue, increased lactate production, and hypoperfusion in both obese human and animal models ([@B1],[@B2]). Hypoxia was found to cause insulin resistance in 3T3-L1 adipocytes and human subcutaneous abdominal adipocytes ([@B3]). However, the role of hypoxia in adipose tissue during obesity and insulin resistance remains unclear. Regulation of hypoxia-mediated responses is mainly dependent on the hypoxia-inducible factor (HIF) family. HIFs are nuclear transcription factors and function as oxygen-sensitive α subunit and β heterodimers (ARNT). All isoforms of HIFα, HIF1α, HIF2α, and HIF3α require the ubiquitously expressed subunit aryl hydrocarbon nuclear translocator (ARNT or HIF1β) as an obligate heterodimerization partner for activation of target genes. HIF1α, HIF2α, HIF3α, and ARNT are all expressed in adipose tissue ([@B4]--[@B6]). HIF function is primarily regulated by HIF1α protein stability. Under normoxia, HIF1α is hydroxylated by prolylhydroxylase (PHD). Following hydroxylation, HIF1α is ubiquitinated by the E3 ubiquitin ligase, von Hippel-Lindau tumor suppressor (VHL) and degraded via the proteasome pathway. Conversely, under hypoxia, hydroxylation is inhibited, leading to stabilization of the α subunit, heterodimerization with ARNT, and activation of HIF target genes ([@B7]).

To investigate the role of hypoxia in obesity and insulin resistance, adipocyte-specific ARNT knockout (*Arnt*^∆Adipo^) mice and adipocyte-specific HIF1α knockout (*Hif1α*^∆Adipo^) mice were generated with the Cre/LoxP system using the adipose-specific aP2-Cre transgene ([@B8]). Both mouse lines exhibit similar metabolic phenotypes, including reduced fat formation, protection from high-fat diet (HFD)-induced obesity, and insulin resistance, suggesting a role for HIF1 in the pathogenesis of obesity and insulin resistance. Taken together, the findings of this study reveal an essential role of HIF1α in controlling adipose mass and function and provide a potential therapeutic target of obesity and insulin resistance.

RESEARCH DESIGN AND METHODS {#s5}
===========================

*Arnt*-floxed (*Arnt*^F/F^) ([@B9]) and *Hif1α*-floxed (*Hif1α*^F/F^) ([@B10]) mice containing loxP sites flanking exons 6 and 13--15, of the *Arnt* and *Hif1α* genes, respectively, were crossed with mice harboring the Cre recombinase under control of the aP2 promoter (aP2-Cre mice). All mice were on the C57BL/6 background, and only male mice were used for experiments. Primers used to assess recombination and routine genotyping for the *Arnt* and *Hif1α* allele are listed in [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1). Male mice were housed in temperature- and light-controlled rooms and supplied with water and pelleted NIH-31 chow diet (10% kcal consisting of fat) ad libitum. In the HFD study, 6-week-old male mice were given an HFD (60% kcal consisting of fat; BioServ, Frenchtown, NJ) for 12 weeks. All animal studies were performed in accordance with Institute of Laboratory Animal Resources guidelines and approved by the National Cancer Institute Animal Care and Use Committee.

Metabolic assays. {#s6}
-----------------

For glucose tolerance test (GTT), mice were fasted for 16 h, blood was drawn, and mice were injected intraperitoneally with 1 g/kg glucose. For insulin tolerance test (ITT), mice were fasted for 4 h, blood was drawn, and then mice were injected intraperitoneally with 1 unit/kg body wt insulin (Humulin R; Eli Lilly, Indianapolis, IN).

Hyperinsulinemic-euglycemic clamps were performed in awake mice fasted for 12 h as previously described ([@B11]) with modifications. Primed-continuous infusion of \[3-3H\]glucose was used: 2.5 µCi bolus, 0.05 µCi/min during the basal state and 0.1 µCi/min during the clamp period. Insulin (Humulin R) was infused as a bolus of 18 mU/kg over a period of 3 min, followed by continuous insulin infusion at the rate of 3.5 mU/kg lean mass/min (in *Hif1α*^F/F^ mice) and 9.4 m/kg lean mass/min (in *Hif1α*^∆Adipo^ mice) to raise plasma insulin concentration to 4 ng/mL.

In vivo insulin stimulation and analysis of insulin signaling. {#s7}
--------------------------------------------------------------

Mice were fasted overnight, and then injected via the vena cava with 5 units of Humulin R under anesthesia. Liver, quadriceps, and white adipose tissue were collected after 5 min and stored at --80°C until use. Total Akt and phospho-Akt (Ser473) antibodies were from Cell Signaling Technologies (Danvers, MA).

Body composition, food intake, and metabolic rate. {#s8}
--------------------------------------------------

Body composition was measured in nonanesthetized mice using an Echo3-in-1 nuclear magnetic resonance (NMR) analyzer (Echo Medical Systems, Houston, TX). Cumulative food intake was measured in 6- to 8-week-old male mice maintained on regular chow for 2 weeks and 10- to 12-week-old mice fed an HFD for 4--6 weeks. Mice were housed individually in their home cages a week prior to recording food intake. Metabolic efficiency was calculated as the ratio of weight gain to energy consumed during a 2-week period. Total and resting metabolic rates were measured by indirect calorimetry using the Oxymax system (Columbus Instruments, Columbus, OH) ([@B12]). Mice had free access to food and water during the measurements and were allowed to adapt to metabolic cages for 24 h prior to data collection. Following an adaptation period, data were recorded for 24 h at 24 and 30°C for an additional 24 h. Four mutant and four control mice were tested at the same time, and each mouse was tested every 20 min. Motor activities were measured by an infrared beam interruption (Opto-Varimex mini, Columbus Instruments), and resting was defined as time points with ambulation equal to zero. Diet-induced thermogenesis and β3 adrenergic thermogenesis were measured as previously described ([@B12],[@B13]).

Biochemical assays. {#s9}
-------------------

Fasted serum insulin was measured by use of an ELISA kit (Crystal Chem). Fasted serum cholesterol, free fatty acids (FFAs), and triglycerides were measured using reagents from Wako. Adiponectin serum levels were measured with a mouse adiponectin ELISA kit (ALPCO). Serum resistin was measured with an ELISA kit (R&D).

RNA and protein analysis. {#s10}
-------------------------

Quantitative PCR (qPCR) reactions were carried out on an ABI Prism 7900HT sequence detection system (Applied Biosystems). Primer sequences are listed in [Supplementary Table 2](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1). Tissues were lysed by use of radioimmunoprecipitation assay for whole cell extract. The membranes were incubated with antibodies against total Akt, phospho-Akt (Ser473), SOCS3, total STAT3, phospho-STAT3 (Cell Signaling Technologies, Danvers, MA), and Arnt and Histone ^1^H (Santa Cruz Biotechnology, Santa Cruz, CA). The signals obtained were normalized to β-actin (Millipore Corp, Temecula, CA) for whole cell extracts.

Isolation of adipocytes and macrophage of stromal vascular fraction and microarray analysis. {#s11}
--------------------------------------------------------------------------------------------

Adipocytes and macrophage of stromal vascular fraction (SVF-Mϕ) were isolated from epididymal white adipose tissue (WAT) as previously described ([@B14]). Dye-coupled cDNAs were purified with a MiniElute PCR purification kit (Qiagen) and hybridized to an Agilent 44 K mouse 60-mer oligo microarray (Agilent Technologies). The procedures were repeated for replicate experiments with independent hybridization and processing and the data processed and analyzed by Genespring GX software (Agilent Technologies).

Histology. {#s12}
----------

Paraffin-embedded tissue sections were stained with hematoxylin-eosin (H-E) using a standard protocol. Quantification of adipocyte area was done on H-E--stained sections using ImageTool software.

Data analysis. {#s13}
--------------

Results were expressed as means ± SD. Differences between groups were examined for statistical significance with Student *t* test. A *P* value of \< 0.05 was considered statistically significant.

RESULTS {#s14}
=======

Generation and characterization of *Arnt^∆Adipo^* and *Hif1α^∆Adipo^* mice. {#s15}
---------------------------------------------------------------------------

For examination of the role of HIF transcription factors in obesity and insulin resistance, *Arnt* and *Hif1α* genes were disrupted in adipocytes. To estimate the extent of cell-specific disruption of the *Arnt* and *Hif1α* loci, PCR analysis was used. A PCR amplicon for the *Arnt*-null allele amplified as a 340 base pair product and was detected in genomic DNA isolated from adipocytes or adipose tissue of *Arnt*^∆Adipo^ mice and not in adipose DNA isolated from *Arnt*^F/F^ mice. In contrast, the floxed allele was the only band detected in adipose tissue from *Arnt*^F/F^ mice and from all nonadipose tissues in *Arnt*^∆Adipo^ mice ([Fig. 1*A*](#F1){ref-type="fig"}). The *Hif1α*-null amplicon amplified as a 355 base pair product was detected in genomic DNA isolated from adipose tissue of *Hif1α*^∆Adipo^ mice, and was not detected in adipose tissue DNA isolated from *Hif1α*^F/F^ mice. The null allele was only detected in adipose tissue and not in liver, skeletal muscle, spleen, or kidney from *Hif1α*^∆Adipo^ mice ([Fig. 1*B*](#F1){ref-type="fig"}). The expression of Arnt mRNA was specifically decreased in WAT and brown adipose tissue (BAT) by 50% in the *Arnt*^∆Adipo^ mice compared with *Arnt*^F/F^ mice; no decrease was evident from liver or skeletal muscle. In addition, qPCR showed nearly absent expression of ARNT mRNA in the adipocytes of *Arnt*^∆Adipo^ mice ([Fig. 1*C*](#F1){ref-type="fig"}). Similar results were obtained from tissues of *Hif1α*^∆Adipo^ mice, where an \~88% decrease in HIF1α mRNA from adipocytes was observed ([Fig. 1*D*](#F1){ref-type="fig"}). Nuclear ARNT protein expression in *Arnt*^∆Adipo^ mice was also markedly decreased ([Supplementary Fig. 1A](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). To confirm that loss of ARNT was of functional significance, the extent of activation of the ARNT-dependent aryl hydrocarbon receptor (AhR) pathway upon 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) challenge was determined. Induction of the AHR target gene *Cyp1a1* was markedly attenuated in WAT and BAT of *Arnt*^∆Adipo^ mice ([Supplementary Fig. 1*B* and *C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). However, no significant difference in the extent of induction of CYP1A1 mRNA was noted in liver or skeletal muscle compared with *Arnt*^F/F^ mice ([Supplementary Fig. 1*D* and *E*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). These results demonstrate adipocyte-specific knockout of the *Arnt* and *Hif1α* genes in mice.

![Adipocyte-specific disruption of the *Arnt* and *Hif1a* genes via Cre-loxP--mediated recombination. *A* and *B*: PCR diagnostic for aP2-Cre--mediated recombination of the *Arnt* or *Hif1α* allele in genomic DNA isolated from adipocytes or tissue of *Arnt*^F/F^ and *Arnt*^∆Adipo^ or *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice. *C* and *D*: qPCR analysis of *Arnt* mRNA expression in the tissues (*left panel*) or adipocytes (*right panel*) from *Arnt*^F/F^ and *Arnt*^∆Adipo^ or *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice. For qPCR analysis, the expression was normalized to β-actin. Data are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 compared with floxed littermates.](2484fig1){#F1}

*Arnt*^∆Adipo^ or *Hif1α*^∆Adipo^ mice are resistant to diet-induced weight gain. {#s16}
---------------------------------------------------------------------------------

To explore the role of HIF1 in fat metabolism and glucose homeostasis, male mice were fed either a chow diet or HFD. When fed a chow diet, *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice grew at a rate similar to that of *Arnt*^F/F^ and *Hif1α*^F/F^ mice, respectively. However, 12 weeks of HFD led to weight gain in *Arnt*^F/F^ and *Hif1α*^F/F^ mice, while *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice were resistant to the HFD-induced weight gain ([Supplementary Fig. 2*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 2*A*](#F2){ref-type="fig"}). NMR measurements confirmed that the body fat mass and the ratio of fat and body mass of *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice fed an HFD were decreased compared with *Arnt*^F/F^ and *Hif1α*^F/F^ mice, respectively ([Supplementary Fig. 2*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 2*B*](#F2){ref-type="fig"}). The adipocyte size in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice was significantly decreased compared with *Arnt*^F/F^ and *Hif1α*^F/F^ mice, respectively, after 12 weeks of HFD ([Supplementary Fig. 2*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 2*C*](#F2){ref-type="fig"}). To explore the mechanism of reduced adiposity in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice, cumulative food intake, metabolic efficiency, and metabolic rates were measured in young mice maintained on chow diet and in mice fed an HFD for 4--7 weeks, which is before the difference between control and mutant mice became apparent. There were no significant differences in weight, cumulative food intake, or metabolic efficiency between *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice maintained on chow diet ([Supplementary Fig. 3*A*--*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). Similarly, indirect calorimetry performed at 24°C and thermoneutrality (30°C) on the same set of mice did not reveal significant differences in metabolic rate, respiratory exchange ratio (RER), or activity between *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice fed chow diet ([Supplementary Fig. 3*D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). A short 4-day exposure to HFD caused comparable increases in body weight and resting metabolic rate in *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice, indicating that adipose-specific inactivation of *Hif1α* did not alter the acute thermogenic response to HFD ([Supplementary Fig. 3*E* and *F*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). These results indicate that it takes a long time for the adipose tissue to get big enough to be hypoxic and that Hif1α expression was significantly induced, resulting in activation of HIF1 target genes such as *Vegf* and *Glut1* ([Supplementary Fig. 7](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). After 4--6 weeks on an HFD, the cumulative food intake remained similar between *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice; however, the metabolic efficiency was lower in the Hif1α^∆Adipo^ mice, suggesting an increase in the metabolic rate ([Fig. 3*A*](#F3){ref-type="fig"}). Indirect calorimetry performed at 24°C on week 7 of HFD did not reveal a significant difference in resting or total oxygen consumption between the genotypes, while at 30°C these parameters tended to be higher in *Hif1α*^∆Adipo^ mice compared with controls ([Supplementary Fig. 3*G*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). *Hif1α*^∆Adipo^ mice had reduced resting and total RER at 30°C during resting phase (daytime) and active phase (nighttime), suggesting increased fatty acid oxidation ([Fig. 3*C* and *D*](#F3){ref-type="fig"}) and a tendency toward increased activity ([Fig. 3*E* and *F*](#F3){ref-type="fig"}). All of these changes in *Hif1α*^∆Adipo^ mice could contribute to the decreased metabolic efficiency and weight gain on an HFD compared with *Hif1α*^F/F^ mice. However, it is unlikely that resistance to HFD was caused by activated BAT thermogenesis because the response to mild cold measured as the difference in metabolic rate at thermoneutral and room temperature and the response to a maximal dose of the β3-adrenergic agonist CL316243, which specifically stimulates BAT thermogenesis, were similar in both strains ([Supplementary Fig. 3*H*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)).

![Disruption of Hif1α protected mice from HFD-induced obesity. *A*: Typical growth curves of *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice maintained on chow diet (*left panel*) or HFD (*right panel*) (*n* = 6--8/group). *B*: Body composition by NMR to show the fat mass and fat mass ratio in *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice after 12 weeks of HFD (*n* = 5/group). *C*: Representative H-E--stained WAT sections and quantification of adipocyte size from *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice after 12 weeks of HFD (*n* = 5/group). Data are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 compared with floxed littermates. (A high-quality digital representation of this figure is available in the online issue.)](2484fig2){#F2}

![Energy balance in *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice. *A* and *B*: Cumulative food intake and metabolic efficiency for 2 weeks in *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice after 4--6 weeks of HFD. BW, body weight. *C* and *D*: Resting and total RER; *V*C[o]{.smallcaps}~2~/*V*[o]{.smallcaps}~2~. *E* and *F*: Ambulatory and total activity levels. *A*--*F* were measured in the same set of *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice. Indirect calorimetry (*C*--*F*) was performed after 7 weeks of HFD at 24°C and 30°C (thermoneutrality) during resting phase (daytime \[D\]) and active phase (nighttime \[N\]) (*n* = 6--8/group). Data are means ± SEM. \**P* \< 0.05, \*\**P* \< 0.01 compared with floxed littermates.](2484fig3){#F3}

HIF1 deficiency in adipocytes improves HFD-induced glucose intolerance and insulin resistance. {#s17}
----------------------------------------------------------------------------------------------

To explore the role of adipocyte HIF1 deficiency in obesity-induced insulin resistance, GTTs and ITTs were performed. When mice were fed a chow diet, there were no significant differences in GTT and ITT between *Arnt*^F/F^ and *Arnt*^∆Adipo^ mice ([Supplementary Fig. 4*A* and *C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). However, GTT revealed that after 11 weeks of HFD challenge, *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice displayed significantly reduced blood glucose compared with *Arnt*^F/F^ and *Hif1α*^F/F^ mice after glucose loading ([Supplementary Fig. 4*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 4*A*](#F4){ref-type="fig"}). Moreover, serum insulin was significantly decreased in *Hif1α*^∆Adipo^ mice during GTT ([Fig. 4*B*](#F4){ref-type="fig"}). ITT showed a significant improvement in insulin sensitivity by adipose HIF1 disruption ([Supplementary Fig. 4*D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 4*C*](#F4){ref-type="fig"}). Moreover, fed glucose, fasted glucose, and fasted serum insulin levels were significantly lower in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice compared with *Arnt*^F/F^ and *Hif1α*^F/F^ mice, respectively, after 12 weeks of HFD. The calculated homeostasis model assessment (HOMA) measure of insulin resistance was significantly decreased in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice ([Table 1](#T1){ref-type="table"}). *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice also had reduced fasted serum triglycerides and FFA levels consistent with improved glucose tolerance and insulin sensitivity in these mice ([Table 1](#T1){ref-type="table"}). Although body mass was similar between *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice after 4 weeks, 6 weeks, and 8 weeks of HFD, GTT and ITT revealed that glucose tolerance and insulin sensitivity were improved in *Hif1α*^∆Adipo^ mice from 4 weeks on an HFD ([Supplementary Fig. 5*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). After 6 weeks of HFD challenge, fasted glucose was similar while fasted insulin levels and HOMA index in *Hif1α*^∆Adipo^ mice were significantly decreased ([Supplementary Fig. 5*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). These results indicated that HIF1 disruption in adipocytes improved HFD-induced glucose tolerance and insulin resistance before the onset of the decrease in body mass.

![Hif1α disruption in adipocytes improved HFD-induced glucose intolerance and insulin resistance. *A* and *B*: Blood glucose levels and serum insulin levels in 2-h GTT 12 weeks after HFD (*n* = 6--8/group). Inset graphs in *A* and *B* depict the respective analysis of the area under the curve (AUC). *C*: ITT 12 weeks after HFD (*n* = 6--8/group). Data are means ± SD. \**P* \< 0.05 compared with *Hif1α*^∆Adipo^ littermates. *D*: Time courses of blood glucose during the hyperinsulinemic-euglycemic clamp. *E* and *F*: Plasma glucose and insulin levels in the basal state and during the clamp. *G*: GIR during the clamp. *H*: Basal and clamp endogenous glucose production (EGP), GIR, whole-body glucose disposal (Rd), and glucose uptake in skeletal muscle, WAT, and BAT. The hyperinsulinemic-euglycemic clamp (*D*--*H*) was performed after 15 weeks of HFD (*n* = 6/group). Data are means ± SEM. \**P* \< 0.05 compared with floxed littermates.](2484fig4){#F4}

###### 

Metabolic parameters after 12 weeks of HFD

  Genotype                            *Arnt*^F/F^   *Arnt*^∆Adipo^                                    *Hif1a*^F/F^   *Hif1α*^∆Adipo^
  ----------------------------------- ------------- ------------------------------------------------- -------------- -------------------------------------------------
  Fasting glucose (mg/dL)             150 ± 21.7    106 ± 21.5[**\***](#t1n1){ref-type="table-fn"}    172 ± 32.5     131 ± 19.8[**\***](#t1n1){ref-type="table-fn"}
  Fed glucose (mg/dL)                 269 ± 28.1    139 ± 27.9[†](#t1n2){ref-type="table-fn"}         206 ± 23.5     149 ± 30.4[†](#t1n2){ref-type="table-fn"}
  Fasting serum insulin (ng/mL)       3.6 ± 1.4     2.1 ± 0.8[**\***](#t1n1){ref-type="table-fn"}     2.6 ± 0.6      1.1 ± 0.2[†](#t1n2){ref-type="table-fn"}
  HOMA index                          31.7 ± 8.6    13.8 ± 7.6[†](#t1n2){ref-type="table-fn"}         27.9 ± 10.4    8.4 ± 1.8[†](#t1n2){ref-type="table-fn"}
  Fasted serum triglyceride (mg/dL)   124 ± 42.1    78.4 ± 7.5[**\***](#t1n1){ref-type="table-fn"}    162 ± 38.8     99.4 ± 19.8[†](#t1n2){ref-type="table-fn"}
  Fasted serum cholesterol (mg/dL)    182 ± 37.6    169 ± 43.6                                        196 ± 45.8     160 ± 24.1
  Fasted serum FFA (mmol/L)           1.88 ± 0.42   1.07 ± 0.39[**\***](#t1n1){ref-type="table-fn"}   1.63 ± 0.35    1.09 ± 0.30[**\***](#t1n1){ref-type="table-fn"}

Data are means ± SD.

\**P* \< 0.05.

†*P* \< 0.01 compared with controls.

A hyperinsulinemic-euglycemic clamp was performed in *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice after 15 weeks of HFD to further characterize in vivo insulin action. In the basal state, *Hif1α*^∆Adipo^ mice had significantly reduced plasma glucose and insulin levels; basal endogenous glucose production (EGP) was similar between genotypes ([Fig. 4*D*--*F* and *H*](#F4){ref-type="fig"}). During the clamp, insulin was infused to maintain plasma insulin levels at ∼4 ng/mL ([Fig. 4*F*](#F4){ref-type="fig"}), and the glucose infusion rate (GIR) was adjusted in order to maintain blood glucose levels in *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice at similar levels ([Fig. 4*D*, *E*, and *G*](#F4){ref-type="fig"}). GIR was significantly increased in *Hif1α*^∆Adipo^ mice ([Fig. 4*G* and *H*](#F4){ref-type="fig"}), which confirmed improved whole-body insulin sensitivity in *Hif1α*^∆Adipo^ mice. During the clamp, insulin induced a more marked suppression of EGP in *Hif1α*^∆Adipo^ mice, suggesting increased insulin sensitivity in the liver. Whole-body glucose disposal (Rd) and glucose uptake into skeletal muscle and adipose tissue were significantly increased in *Hif1α*^∆Adipo^ mice ([Fig. 4*H*](#F4){ref-type="fig"}). Taken together, these data suggest that adipose selective inactivation of HIF1 caused increased insulin sensitivity in major insulin target tissues, liver, skeletal muscle, and fat.

Insulin action was further investigated in WAT, liver, and skeletal muscle ([@B15]). Both ARNT and HIF1α deficiency in adipocytes improved insulin signaling pathways in WAT, liver, and skeletal muscle, as revealed by increased phosphorylation of Akt (ser473) ([Fig. 5*A*--*C*](#F5){ref-type="fig"}). These findings indicated that HIF1 deficiency in adipocytes improved HFD-induced glucose tolerance and insulin resistance, which is in support of the hyperinsulinemic-euglycemic clamp studies.

![Arnt and Hif1α disruption in adipocytes enhanced insulin signaling pathways. Insulin-stimulated Akt phosphorylation (Ser473) in WAT (*A*), liver (*B*), and skeletal muscle (*C*) of *Arnt*^F/F^ and *Arnt*^∆Adipo^ and *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice.](2484fig5){#F5}

Expression of genes altered in ARNT- and HIF1-deficient adipose tissue. {#s18}
-----------------------------------------------------------------------

After 12 weeks of HFD, HIF1α was significantly elevated, resulting in activation of target genes such as *Glut1* and *Vegf* ([Supplementary Fig. 6*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). On a chow diet, HIF1 target genes and adiponectin expression were similar between *Hif1a*^F/F^ and *Hif1α*^∆Adipo^ mice ([Supplementary Fig. 6*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). In addition, there was no significant nuclear HIF1α protein expression in WAT from chow-fed wild-type mice, while it was significantly induced in HFD-fed mice and diminished in *Hif1α*^∆Adipo^ mice ([Supplementary Fig. 6*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). Thus, the phenotype of *Hif1α*^∆Adipo^ mice is similar to *Hif1a*^F/F^ mice on a chow diet but different on an HFD. In contrast to HIF1α protein, HFD treatment did not elevate HIF2α protein expression and there was no increase in *Hif1α*^∆Adipo^ mice ([Supplementary Fig. 6*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)).

Gene expression profiling of WAT after 12 weeks of HFD in *Arnt*^F/F^ and *Arnt*^∆Adipo^ mice or *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice showed that the HIF1 target genes *Glut1* and *Vegf* were decreased in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Supplementary Fig. 7*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 6*A*](#F6){ref-type="fig"}). Expression of genes involved in adipogenesis and glucose metabolism, *Pparg*, *C/EBPα*, *Cfd*, and *Glut4*, were upregulated in WAT of *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice compared with *Arnt*^F/F^ and *Hif1α*^F/F^ mice, respectively, on an HFD. Importantly, total serum adiponectin, the high--molecular weight (HMW) form of adiponectin, and the ratio of HMW to total adiponectin were increased in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice on a 12-week HFD ([Supplementary Fig. 7*B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 6*B*](#F6){ref-type="fig"}). HMW adiponectin and ratio of HMW to total adiponectin began to be increased following 6 weeks of HFD before the decrease in body weight ([Supplementary Fig. 5*D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). Previous studies showed that overexpression of a constitutively active form of HIF1α initiates adipose tissue fibrosis and insulin resistance ([@B16]). In agreement with this finding, expression of the fibrosis related genes *Lox*, *Col1a1*, *Col3a1*, and *Loxl1* were decreased in *Arnt*^∆Adipo^ or *Hif1α*^∆Adipo^ mice ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Supplementary Fig. 7*C*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 6*C*](#F6){ref-type="fig"}). Expression of the inflammation-related genes *Tnfα* and *Pai-1* was downregulated in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Supplementary Fig. 7*A*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 6*A*](#F6){ref-type="fig"}). Macrophage marker F4/80 staining of adipose tissue sections revealed that macrophage infiltration to WAT decreased significantly in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice. Expression of mRNAs encoding the macrophage markers F4/80 and CD68 were also decreased in *Arnt*^∆Adipo^ mice and *Hif1α*^∆Adipo^ mice ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Supplementary Fig. 8*A* and *B*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). Because it was reported that the aP2 promoter is expressed in macrophage ([@B17]), the possibility that HIF1 was disrupted in macrophage was investigated by determining *Arnt* gene disruption in peritoneal macrophage (P-Mϕ) from *Arnt*^∆Adipo^ mice. Loss of ARNT in peritoneal macrophage of *Arnt*^∆Adipo^ mice was minimal in contrast to much lower ARNT mRNA levels in *Arnt*^∆Adipo^ mouse adipocytes ([Fig. 7*A*](#F7){ref-type="fig"}).

![Expression of genes related to insulin resistance in Hif1α disrupted WAT. WAT from *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice after 12 weeks of HFD was analyzed. *A*: qPCR analysis of various mRNAs. *B*: Total adiponectin levels, HMW adiponectin, and the ratio of HMW to total adiponectin. *C*: qPCR analyses of fibrosis-related gene expression. *D*: qPCR analyses of *Socs3* expression. *E*: Western blot analysis of SOCS3 expression and STAT3 phosphorylation (*left panel*) and quantitation of SOCS3 expression and STAT3 phosphorylation (*right panel*). Relative protein levels were normalized to levels for floxed littermates. For qPCR analysis, expression was normalized to β-actin. Data are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 compared with floxed littermates.](2484fig6){#F6}

![Gene expression in adipocytes and SVF-Mϕ after HFD. *A*: qPCR analysis of *Arnt* mRNA expression in the peritoneal macrophages (P-Mϕ) (*B*) and qPCR analysis of HIF1α, SOCS3, and adiponectin mRNA expression in adipocytes and SVF-Mϕ (*C*) of *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice after 12 weeks of HFD. The expression was normalized to β-actin. Data are means ± SD. \**P* \< 0.05, \*\**P* \< 0.01 compared with floxed littermates.](2484fig7){#F7}

Previous studies demonstrated that SOCS3 mRNA is elevated in WAT of diet-induced obesity (DIO) mice ([@B18],[@B19]). Further, haploinsufficiency of SOCS3 significantly protected mice against the development of DIO and associated metabolic complications ([@B20]). Consistent with these findings, SOCS3 mRNA was also found to be downregulated in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice, as revealed by microarray analysis ([Supplementary Table 1](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1)). Expression of SOCS3 mRNA in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice was significantly lower than that in *Arnt*^F/F^ and *Hif1α*^F/F^ mice, respectively ([Supplementary Fig. 7*D*](http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1); [Fig. 6*D*](#F6){ref-type="fig"}). Expression of SOCS3 protein was also significantly decreased in *Hif1α^∆Adipo^* mice ([Fig. 6*E*](#F6){ref-type="fig"}). Adipocytes and macrophage of stromal vascular fraction (SVF-Mϕ) were prepared from WAT of *Hif1α^∆Adipo^* and *Hif1α*^F/F^ mice after 12 weeks of HFD. In adipocytes, no significant expression of HIF1α mRNA in Hif1α^∆Adipo^ mice was found. After 12 weeks of HFD, expression of SOCS3 in adipocytes of *Hif1α*^∆Adipo^ mice was \~80% decreased compared with that in *Hif1α*^F/F^ mice. Adiponectin expression was upregulated in adipocytes of *Hif1α*^∆Adipo^ mice ([Fig. 7*B*](#F7){ref-type="fig"}). Consistent with data obtained in P-Mϕ, the expression of HIF1α, SOCS3, and adiponectin (adiponectin expression being nearly undetectable in SVF-Mϕ) in SVF-Mϕ were not significantly different between *Hif1α*^∆Adipo^ and *Hif1α*^F/F^ mice after 12 weeks of HFD ([Fig. 7*C*](#F7){ref-type="fig"}).

Previous studies revealed that SOCS3 can inhibit adiponectin production via JAK2-STAT3--dependent mechanisms in adipocytes ([@B21]). Since inactivation of STAT3 may be involved in the inhibition of adiponectin production by SOCS3, tyrosine phosphorylation of STAT3 was assessed in WAT from *Hif1α*^F/F^ and *Hif1α*^∆Adipo^ mice. Indeed, tyrosine phosphorylation of STAT3 was significantly induced in parallel with increased adiponectin level in *Hif1α*^∆Adipo^ mice ([Fig. 6*E*](#F6){ref-type="fig"}). These results suggest that the SOCS3 and adiponectin pathway is involved, in part, in the improvement of HFD-induced insulin resistance in *Hif1α*^∆Adipo^ mice.

DISCUSSION {#s19}
==========

Cellular hypoxia is observed in adipose tissue of obese individuals ([@B22]). However, the role of hypoxia in adipose tissue during obesity and insulin resistance remains unclear. In the current study, adipocyte-specific disruption of HIF1α or its heterodimerization partner, ARNT, were shown to protect against HFD-induced obesity and insulin resistance. HIF1 signaling may regulate SOCS3 and adiponectin, thus providing a mechanistic clue by which HIF1 exacerbates whole-body insulin resistance. These findings indicate a central role for adipocyte HIF1 signaling in the pathogenesis of obesity and insulin resistance.

In the obese mouse model, hypoxia occurs specifically in WAT, and the response to adipose hypoxia may lead to insulin resistance ([@B23]). HIF1, the main mediator of the hypoxia response in adipose tissue, is almost undetectable in lean mice but significantly increased in obese mice resulting in induction of the HIF1 target genes *Glut1 and Pdk1* ([@B2]). Moreover, overexpression of a constitutively-active HIF1α in adipose tissue leads to glucose intolerance and insulin resistance ([@B16]). These studies are consistent with results of the present work showing that ablation of ARNT or HIF1α in adipose tissue improved HFD-induced obesity and insulin resistance.

In *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice, adipogenesis-related genes such as *Pparg*, *C/ebpα*, *Cfd*, and *Glut4* were increased and adipocyte size and mass reduced after HFD challenge, consistent with the notion that enhanced adipogenesis does not correlate with obesity ([@B24],[@B25]). These results provide in vivo evidence that hypoxia inhibits adipogenesis in an HIF1-dependent manner ([@B26]). The reduced adiposity in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice was independent of food intake and may be due in part to increased energy expenditure. *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice exhibited higher serum total adiponectin levels. Others found that in obese mice, adiponectin treatment increased energy expenditure and decreased mouse fat mass by upregulating expression of uncoupling protein 2 (UCP2) and increasing fatty acid oxidation ([@B27]--[@B30]). In addition, decreased vascular endothelial growth factor (VEGF) mRNA in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice WAT suggests that lower VEGF as a result of loss of HIF1 may also contribute to the decreased adiposity in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice. Indeed, VEGF inhibitors were shown to decrease adipose mass following HFD ([@B31]).

It has previously been claimed that aP2 expression is induced in activated macrophages ([@B17]). However, in *Hif1α*^∆Adipo^ mice the knockout efficiency of HIF1α in SVF-Mϕ was very low---consistent with recent reports showing that the efficiency of Cre recombination in macrophage was much less than that in adipocytes ([@B14],[@B32]--[@B34]).

Loss of HIF1 in adipose tissue can improve whole-body glucose intolerance after HFD, mainly due to enhanced insulin signaling in WAT, liver, and skeletal muscle. The current study revealed that SOCS3 is regulated by HIF1 in WAT. Inflammatory factors such as tumor necrosis factor-α, interleukin-6, and lipopolysaccharide also inhibit insulin signaling via upregulation of SOCS3 ([@B18],[@B35]). SOCS3 can bind to phosphorylated tyrosine 960 of the insulin receptor ([@B36]) and inhibit insulin receptor autophosphorylation ([@B37]), IRS1 phosphorylation, and downstream insulin signaling ([@B35]). SOCS3 deficiency increases insulin-stimulated glucose uptake in adipocytes ([@B19]). Therefore, decreased SOCS3 in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice may account for the improved insulin signaling in WAT. The increased adiponectin expression and secretion was accompanied by a decrease of SOCS3 and activation of STAT3 in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice. Adiponectin improves insulin signaling in both skeletal muscle and the liver ([@B30]). This can explain the present findings that insulin sensitivity in liver and muscle was improved in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice compared with *Arnt*^F/F^ and *Hif1α*^F/F^ mice. In addition, HMW adiponectin levels and the ratio of HMW to total adiponectin were increased in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice. Indeed, HMW adiponectin levels, or the ratio of HMW adiponectin to total adiponectin, are more meaningful markers than total adiponectin levels for predicting insulin resistance and the development of metabolic syndrome ([@B38]). Overexpression of SOCS3 in adipose tissue inhibited local insulin action but improved systemic glucose metabolism, and adiponectin production was increased after HFD ([@B39]). Whereas these data seem paradoxical given the current results, others reported that SOCS3 is elevated in WAT under the pathological conditions of insulin resistance ([@B18],[@B19]) and when SOCS3 is overexpressed SOCS3 levels rise far higher than under normal physiological conditions. In the current study, SOCS3 expression was decreased in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice after HFD. Differences in the model and experimental conditions may account for these different observations. In addition, consistent with the present results, a recent study showed that pioglitazone exerts its effect to improve whole-body insulin sensitivity through the suppression of SOCS3, which is associated with an increase in STAT3 phosphorylation and adiponectin production in WAT ([@B21]). Moreover, *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice also have reduced serum triglycerides and FFAs, which is consistent with studies showing that FFAs and triglycerides impair insulin signaling and induce insulin resistance mainly in liver and muscle ([@B40],[@B41]). It is also of interest that the proinflammatory factors tumor necrosis factor-α and plasminogen activator inhibitor-1 were decreased in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice. These factors are also associated with improved insulin sensitivity of the whole body in *Arnt*^∆Adipo^ and *Hif1α*^∆Adipo^ mice after HFD.

In conclusion, the current study clearly shows that HIF1 in adipose tissue plays an important role in the metabolism of lipid and glucose. The HIF1 effects on insulin sensitivity may be due in part to its direct or indirect regulation of SOCS3 in WAT, whereas the mechanism of its effect on adiposity and obesity is still not clear and requires further investigation. Because loss of HIF1 activity improves metabolic function, compounds that inhibit HIF1 function in adipose tissue might have significant therapeutic potential in reducing obesity and insulin resistance.

This article contains Supplementary Data online at <http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-0174/-/DC1>.
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